GlobeNewswire GlobeNewswire•December 4, 2019
ATLANTA, Dec. 04, 2019 (GLOBE NEWSWIRE)
-- Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader
in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases,
today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will be a featured presenter at the LD Micro Main Event on
Tuesday, December 10, 2019 at 12:40 PM Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Mr. Eiswirth will provide an overview of the company’s business
model and growth strategy and will be available for one-on-one meetings.
In addition, his presentation will be webcast. To access the webcast, please visit
http://wsw.com/ldmicro17/alim at the time of the presentation.
The webcast will also be archived for 90 days and may be subsequently accessed on the Company’s website.
For those interested in attending or for registered attendees who wish to request meetings,
please contact David Scher at david@ldmicro.com or visit
http://www.ldmicro.com for more information.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.
Alimera is presently focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
For more information, please visit http://www.alimerasciences.com.
About ILUVIEN®
The Company’s primary product is ILUVIEN
(fluocinolone acetonide intravitreal implant)
0.19 mg sustained release intravitreal implant,
injected into the back of the eye.
With its CONTINUOUS MICRODOSING™ technology, ILUVIEN is designed to release sub-microgram levels of fluocinolone acetonide,
a corticosteroid, for 36 months,
to reduce the recurrence of disease,
enabling patients to maintain vision longer with fewer injections.
ILUVIEN is approved in the
U.S.,
Canada,
Kuwait,
Lebanon and
the U.A.E
to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure.
In 17 European countries, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered
insufficiently responsive to available therapies.
In March 2019, ILUVIEN received approval in the 17 countries under
the Mutual Recognition Procedure for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
The
17 European countries include the
U.K.,
Germany,
France,
Italy,
Spain,
Portugal,
Ireland,
Austria,
Belgium,
Denmark,
Norway,
Finland,
Sweden,
Poland,
Czech Republic,
the Netherlands, and
Luxembourg.
The regulatory process is now in the national phase in which the European member states have finalized or are expected to finalize
the label for the new indication to meet each country’s local requirements.
Timeline to this goal varies by each country,
and the non-infectious posterior uveitis indication for ILUVIEN
was launched in
Germany and
the U.K. in 3Q 2019.
ILUVIEN is not approved for treatment of uveitis in the United States.
For press inquiries:
For investor inquiries:
Jules Abraham Scott Gordon
for Alimera Sciences for Alimera Sciences
917-885-7378 scottg@coreir.com
julesa@coreir.com
Recent ALIM News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/23/2024 04:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:54:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:53:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:52:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:52:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:52:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2024 01:51:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:48 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/18/2024 08:30:11 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/16/2024 09:10:24 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/16/2024 08:22:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM